BRAIN Biotech AG expands stake in successful enzyme producer Biocatalysts Ltd.
DGAP-News: BRAIN Biotech AG / Key word(s): Investment
12.05.2021 / 16:30
Zwingenberg, Germany, May 12, 2021
BRAIN Biotech AG expands stake in successful enzyme producer Biocatalysts Ltd.
BRAIN has acquired additional shares in Biocatalysts Ltd.
Biocatalysts strong business trend
Planned additional capacity expansion now targeted earlier
BRAIN Biotech AG has expanded its shareholdings in the successful enzyme producer Biocatalysts Ltd., Wales, to 82.2% by the purchase of additional shares from minority shareholders. Due to the strong business performance at Biocatalysts Ltd. current production capacity will be fully utilised although only coming on stream in early 2021. The 2nd phase of expansion is planned to be accelerated as a result.
TerraScale and iQ International Sign Definitive Share Exchange Agreements to Revolutionize the Green Data Center Market
Combination Creates Unique Innovation Possibilities in Sustainable and Secure Computing Globally
- Combined company to be named TerraScale AG and to be headquartered in Zug, Switzerland.
- Green Cloud services offering to be branded iQ.
- Significant company presence to remain in Germany.
- Company will remain traded publicly at the General Standard of the German stock exchange in Frankfurt.
- The joint company presents a world-first combination of best-in-class green data centers, secure private and public cloud solutions, robust energy storage (Batteries), innovative renewable power management, and leading edge cybersecurity expertise and technologies, all under one unified brand.
artnet AG: Strong Growth at Artnet Auctions Continues in the First Quarter
Gallery Network Increases Memberships and Revenue
Average Monthly Visitors up 35% at 6.2 Million
Paywall Artnet News Pro Creates Additional Revenue Stream
BERLIN, GERMANY and NEW YORK, NY / ACCESSWIRE / May 10, 2021 / Berlin-based Artnet AG, the leading provider of art market data and online-only fine art auctions, increased its revenue and media reach in the first quarter of 2021. Fee-based revenue at
Artnet Auctions rose by 25% year-over-year to 1.2 million USD, continuing on a strong growth trajectory and setting a new revenue record for a first quarter. Top lots in the first quarter included several works by the iconic American artist Jean-Michel Basquiat. In January, his screenprints
USD 4,788,026,030 Total equity and liabilities USD 4,788,084,917
B.3
What are the key risks that are specific to the Issuer?
The Issuer has been established as a special purpose vehicle for the purpose of establishing the programme and issuing multiple series of asset backed securities, holding the relevant underlying precious metals, and entering into, and performing its obligations under, agreements related to the foregoing. The Issuer has, and will have, no assets other than its issued and paid-up share capital, such fees (as agreed) payable to it in connection with the issue of Certificates or entry into other obligations from time to time and any assets on which Certificates or other obligations are secured.
- Different commercialization models currently being explored
BRAIN Biotech AG has successfully completed the first development phase for a novel genome editing CRISPR Cas system applying its advanced metagenomics sequencing and protein engineering capabilities. BRAIN s technology enabled by a novel and independent
Non-CAS9-Nuclease will significantly speed up in-house developments and promises significant economic upside.
Genome editing has lately become one of the most exciting technologies in biotechnology. It allows for the directed and precise insertion, deletion or modification in the genome of a living organism. The CRISPR-CAS system has provided a genetic tool with speed as well as simplicity that was previously unavailable to science.